Hints and tips:
...Smith & Nephew Associated Co’s. Standard Chartered Bank Sun Alliance & London Insurance (RSA Insurance) Tesco Unilever Whitbread & Co....
...It was a direct competitor to Tagamet, a big-selling drug produced by an American company, Smith Kline & French....
...Nicholas Malins-Smith Cambridge, UK...
...kludge, suitable only for investors who wanted exposure to the likes of Psion, Scoot.com and Kalamazoo Computer but expected overall performance to be determined by FTSE 100 old-economy heavyweights such as Glaxo...
...war (FT) Chesapeake Energy preparing bankruptcy filing (Reuters) SoftBank warns of $9.6bn investment losses due to coronavirus (FT) Amundi and Janus Henderson suffer market-induced asset falls (FT) Glaxo...
...The company also named Deborah Waterhouse, chief executive of Glaxo-controlled ViiV Healthcare, to the board....
...(New York Times) Glaxo’s shake-up Big Pharma’s first female chief executive, Emma Walmsley, has overhauled the British drugmaker GlaxoSmithKline and tried to revitalise the lumbering giant....
...O’Melveny, a law firm, has hired David M Smith, Robert T Graffum, and Nicolai M Schwarz-Gondek as partners in its M&A practice from Stradling Yocca Carlson & Rauth. Read more about them here....
...For commentary on Hargreaves Lansdown’s dividend problem, Body Shop’s sale and Glaxo’s adjustments, see this morning’s Lombard column....
...Is Smith & Nephew the one that got away? The UK medical device maker has long been seen as a potential target for bigger US rivals....
...Beecham languished by comparison, later merging with Smith Kline and being subsequently subsumed within the GSK group....
...Smith & Nephew led Friday’s FTSE gainers, up 3.8 per cent to £10.65, on second-quarter sales and earnings that beat consensus estimates....
...Believing that the science underlying beta blockers had other uses, he left ICI for the greater freedom offered by Smith Kline. Black’s hopes were realised....
...“At Glaxo[SmithKline] we persuaded them they should reprioritise buy-backs over infill acquisitions because it was our view, and the management’s view, that the share price was substantially below intrinsic...
...He started his career at French pharma group Roussel Uclaf and moved to Glaxo France in 1991....
...The consensus was “underestimating the complexity of Advair’s device patents, over-crediting the competition and underestimating Advair’s international potential”, said Justin Smith, MF analyst....
...For investors seeking growth, Jonathan Jackson, head of equities at Killik & Co, prefers shares in Cobham, Smith & Nephew and Bovis Homes....
...Glaxo Smith Kline, BAT, Imperial Tobacco, and BT, for example, all offer prospective yields higher than 4.49per cent....
...So he left ICI for rival Smith Kline....
...Gillie Baerselman, Guildford, Surrey SM: High income funds tend to focus on cash generative companies such as Glaxo, Vodafone, Roche, BP among others....
...BAE Systems fell 5 per cent to 348½p and Smiths Group was down 4.8 per cent to 846½p....
...Glaxo was on a list of potential bidders for ImClone, the US biotech company. Smiths Group rose 3.7 per cent to £10.63, bouncing from a two-month low....
...A few days later, instead of relaxing for the holidays, Mr Stéphenne, head of Smith Kline Biologicals, would be arguing for considerable investment from the full board of the parent company in the US, which...
...Dealers cited the latest mergers and acquisitions developments in the US, where Tishman Speyer, the owner of New York’s Chrysler Center, and Lehman Brothers, are paying $22.2bn for Archstone-Smith, the second...
International Edition